EGFR and glioblastoma: Furthermore, molecular profiling of the patient samples was unable to identify an overall correlation between OS/PFS and EGFRvIII mutations, even though preclinical results from GBM cell lines and xenograft models showed high specificity and effectivity of the antibody–drug conjugate towards EGFRvIII and EGFR amplified tumor cells [28].